• Arcturus reported interim Phase 2 results for ARCT-810 in ornithine transcarbamylase deficiency, describing the drug as generally safe and well tolerated.
• Participants showed improvement in key disease markers, with effects sustained during periods of higher protein intake.
• The group introduced LUNAR 2.0, a next-generation mRNA delivery platform positioned to support lower or less frequent dosing in future programs.
• Dosing of next-generation candidate ARCT-2601 is planned near year-end in patients aged 12 and older within an amended Phase 2 protocol.
• Management plans to present additional details later today in an investor webcast.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arcturus Therapeutics Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260923761420) on September 23, 2026, and is solely responsible for the information contained therein.